Hopper Jonathan Mark
Known title: Chief Medical OfficerCIK: 0001626325
Associated companies
Transaction History
| VCEL | ▲ Buy | Option Exercise | 5,000 | $149K | 6/26/2026 | View on chart |
| VCEL | ▼ Sell | Open Market | 5,000 | $225K | 6/26/2026 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 5,000 | $149K | 6/26/2026 | View on chart |
| VCEL | ▼ Sell | Open Market | 5,000 | $225K | 6/26/2026 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 4,375 | $73K | 6/2/2026 | View on chart |
| VCEL | ▼ Sell | Open Market | 4,375 | $153K | 6/2/2026 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 3,472 | $38K | 4/2/2026 | View on chart |
| VCEL | ▼ Sell | Open Market | 3,472 | $122K | 4/2/2026 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 350 | — | 2/24/2026 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 3,150 | $0 | 2/24/2026 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 1,500 | — | 2/24/2026 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 1,500 | $0 | 2/24/2026 | View on chart |
| VCEL | ▼ Sell | Tax Withholding | 636 | $24K | 2/24/2026 | View on chart |
| VCEL | ▼ Sell | Tax Withholding | 1,335 | $51K | 2/24/2026 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 3,000 | — | 2/18/2026 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 2,325 | $0 | 2/18/2026 | View on chart |
| VCEL | ▼ Sell | Tax Withholding | 982 | $37K | 2/18/2026 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 1,652 | $30K | 12/2/2025 | View on chart |
| VCEL | ▼ Sell | Open Market | 1,652 | $65K | 12/2/2025 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 10,000 | $180K | 9/2/2025 | View on chart |
| VCEL | ▼ Sell | Open Market | 10,000 | $358K | 9/2/2025 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 10,000 | $180K | 6/2/2025 | View on chart |
| VCEL | ▼ Sell | Open Market | 10,000 | $401K | 6/2/2025 | View on chart |
| VCEL | ▼ Sell | Open Market | 10,000 | $495K | 3/3/2025 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 10,000 | $180K | 3/3/2025 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 1,500 | — | 2/24/2025 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 1,500 | $0 | 2/24/2025 | View on chart |
| VCEL | ▼ Sell | Tax Withholding | 636 | $33K | 2/24/2025 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 1,750 | $0 | 2/19/2025 | View on chart |
| VCEL | ▼ Sell | Tax Withholding | 853 | $49K | 2/19/2025 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 2,325 | $0 | 2/18/2025 | View on chart |
| VCEL | ▼ Sell | Tax Withholding | 985 | $56K | 2/18/2025 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 3,000 | — | 2/18/2025 | View on chart |
| VCEL | ▼ Sell | Open Market | 10,000 | $587K | 12/2/2024 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 10,000 | $167K | 12/2/2024 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 10,000 | $110K | 9/3/2024 | View on chart |
| VCEL | ▼ Sell | Open Market | 10,000 | $498K | 9/3/2024 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 10,000 | $110K | 5/20/2024 | View on chart |
| VCEL | ▼ Sell | Open Market | 10,000 | $500K | 5/20/2024 | View on chart |
| VCEL | ▼ Sell | Tax Withholding | 1,379 | $68K | 2/20/2024 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 2,325 | $0 | 2/20/2024 | View on chart |
| VCEL | ▼ Sell | Tax Withholding | 985 | $49K | 2/20/2024 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 1,750 | $0 | 2/20/2024 | View on chart |
| VCEL | ▼ Sell | Tax Withholding | 742 | $37K | 2/20/2024 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 3,000 | $0 | 2/20/2024 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 1,625 | $0 | 2/12/2024 | View on chart |
| VCEL | ▼ Sell | Tax Withholding | 775 | $37K | 2/12/2024 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 5,000 | $55K | 11/20/2023 | View on chart |
| VCEL | ▼ Sell | Open Market | 5,000 | $182K | 11/20/2023 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 1,750 | $0 | 2/19/2023 | View on chart |
| VCEL | ▼ Sell | Tax Withholding | 752 | $22K | 2/19/2023 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 2,325 | $0 | 2/18/2023 | View on chart |
| VCEL | ▼ Sell | Tax Withholding | 1,108 | $33K | 2/18/2023 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 1,625 | $0 | 2/11/2023 | View on chart |
| VCEL | ▼ Sell | Tax Withholding | 840 | $25K | 2/11/2023 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 650 | $0 | 2/6/2023 | View on chart |
| VCEL | ▼ Sell | Tax Withholding | 310 | $9K | 2/6/2023 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 10,000 | $110K | 3/1/2022 | View on chart |
| VCEL | ▼ Sell | Open Market | 10,000 | $414K | 3/1/2022 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 10,000 | $180K | 3/1/2022 | View on chart |
| VCEL | ▼ Sell | Open Market | 6,738 | $279K | 3/1/2022 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 1,750 | $0 | 2/19/2022 | View on chart |
| VCEL | ▼ Sell | Tax Withholding | 730 | $25K | 2/19/2022 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 1,625 | $0 | 2/11/2022 | View on chart |
| VCEL | ▼ Sell | Tax Withholding | 775 | $27K | 2/11/2022 | View on chart |
| VCEL | ▼ Sell | Tax Withholding | 310 | $11K | 2/6/2022 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 650 | $0 | 2/6/2022 | View on chart |
| VCEL | ▼ Sell | Open Market | 9,000 | $361K | 12/22/2021 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 10,000 | $167K | 12/22/2021 | View on chart |
| VCEL | ▼ Sell | Open Market | 5,881 | $236K | 12/22/2021 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 9,000 | $99K | 12/22/2021 | View on chart |
| VCEL | ▲ Buy | Option Exercise | 1,000 | $11K | 12/20/2021 | View on chart |
| VCEL | ▼ Sell | Open Market | 1,000 | $40K | 12/20/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Truist lowers Vericel price target to $52
Truist Securities maintained its positive stance on Vericel but reduced its price target to $52. This adjustment places the new target below the current average analyst estimate of $60.57. The move reflects a cautious outlook despite the firm's continued positive assessment of the company.
Truist lowers Vericel price target to $52. Truist Securities maintained its positive stance on Vericel but reduced its price target to $52. This adjustment places the new target below the current average analyst estimate of $60.57. The move reflects a cautious outlook despite the firm's continued positive assessment of the company.